Last reviewed · How we verify
NCT03244709
Tocilizumab Dose-tapering and Interruption in Patients With Giant Cell Arteritis Achieving the Clinical Remission.
Phase 4 trial testing Tocilizumab in Giant Cell Arteritis in 15 participants. Status unknown.
31 December 2017
Quick facts
| Lead sponsor | Hospital of Prato |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 1 January 2015 |
| Primary completion | 31 December 2017 |
| Estimated completion | 31 December 2017 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Tocilizumab (tocilizumab) — full drug profile →
Conditions studied
- Giant Cell Arteritis — all drugs for Giant Cell Arteritis →
Sponsor
Hospital of Prato
Who can join
Adults 18 to 90, any sex, with Giant Cell Arteritis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Interleukin-6 (IL-6), a pro-inflammatory cytokine, has been found to have a crucial role in the pathogenesis of Giant cel arteritis (GCA). Based on this rationale, several recent studies demonstrated the efficacy of tocilizumab (TCZ), an anti-IL-6 targeted monoclonal antibody, for the treatment of patients with refractory GCA. Confirming previous reports,in a recent retrospective study the investigators successfully treated 10 patient with refractory GCA with TCZ. All patients achieved a complete disease remission evaluated by clinical, laboratory, and positron emission tomography (PET). In a considerable number of GCA patients treated with corticosteroids (CS) the therapy may be interrupted with no disease flares. No data are available on the management of patients achieving the remission with TCZ.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03244709
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Tocilizumab
Trials testing the same drug.
- NCT03787290 — Mild-Intensity Whole Body Hyperthermia (WBH) for Major Depressive Disorder · Phase 2 · suspended
- NCT07335562 — A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versu · Phase 3 · recruiting
- NCT06016517 — Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis · not yet recruiting
- NCT06381661 — Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Tra · Phase 2 · not yet recruiting
- NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
Other recruiting trials for Giant Cell Arteritis
Currently open trials in the same condition.
- NCT07084480 — Giant Cell Arteritis - Ways to Precision Medicine · recruiting
- NCT06894602 — Association of Ultrasonographic Temporal Artery Lesions and Relapse in Patients With Giant Cell Arteritis · recruiting
- NCT05935709 — DANIsh VASculitis Database (DANIVAS) · recruiting
- NCT06460142 — Assessing Biomarker in Giant Cell Arteritis and Polymyalgia Rheumatic · recruiting
- NCT06011512 — Risk of Diabetes Mellitus in Patients With Giant Cell Arthritis and Polymyalgia Rheumatica. · recruiting
Other Hospital of Prato trials
Trials by the same sponsor.
- NCT04320277 — Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study. · Phase 2, PHASE3 · unknown
- NCT04190108 — Frequency of Elevated Fecal Calprotectin Levels in Psoriatic Arthritis. · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03244709 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital of Prato
- Last refreshed: 10 August 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03244709.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing